Patents Assigned to Innogenetics
-
Patent number: 8686126Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.Type: GrantFiled: July 19, 2012Date of Patent: April 1, 2014Assignee: Innogenetics N.V.Inventor: Abdurrahman Mithat Bozdayi
-
Publication number: 20130177910Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.Type: ApplicationFiled: March 7, 2013Publication date: July 11, 2013Applicants: Roche Diagnostics GMBH, Innogenetics N.V.Inventors: Innogenetics N.V., Roche Diagnostics GMBH
-
Publication number: 20130171656Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Proteus species, in particular of Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Proteus species, in particular Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, using said new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Proteus species in a sample.Type: ApplicationFiled: March 6, 2013Publication date: July 4, 2013Applicants: ROCHE DIAGNOSTICS GMBH, INNOGENETICS N.V.Inventors: INNOGENETICS N.V., ROCHE DIAGNOSTICS GMBH
-
Patent number: 8426129Abstract: The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04new and HLA-DRB4*01new are disclosed. The present invention relates to methods for typing of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51new. The present invention further provides primers and probes to be used in the methods for typing. A diagnostic kit comprising these primers and probes is also part of the present invention.Type: GrantFiled: April 14, 2008Date of Patent: April 23, 2013Assignee: Innogenetics N.V.Inventors: Ilse De Canck, Guy Mersch, Rudi Rossau
-
Publication number: 20130040284Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.Type: ApplicationFiled: July 19, 2012Publication date: February 14, 2013Applicant: Innogenetics N.V.Inventor: Abdurrahman Mithat BOZDAYI
-
Patent number: 8343493Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.Type: GrantFiled: October 24, 2008Date of Patent: January 1, 2013Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), SanofiInventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
-
Publication number: 20120308594Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.Type: ApplicationFiled: December 9, 2011Publication date: December 6, 2012Applicant: INNOGENETICSInventors: Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
-
Publication number: 20120270208Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.Type: ApplicationFiled: May 23, 2012Publication date: October 25, 2012Applicant: INNOGENETICS, S.A.Inventors: Robert J. DELEYS, Dirk Pollet, Geert Maertens, Hugo Van Heuverswjn
-
Patent number: 8278432Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.Type: GrantFiled: March 29, 2002Date of Patent: October 2, 2012Assignee: Innogenetics N.V.Inventor: Abdurrahman Mithat Bozdayi
-
Patent number: 8163873Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: GrantFiled: November 10, 2008Date of Patent: April 24, 2012Assignee: N.V. Innogenetics S.A.Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
-
Patent number: 8124747Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.Type: GrantFiled: August 27, 2004Date of Patent: February 28, 2012Assignee: InnogeneticsInventors: Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
-
Patent number: 8101351Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 12, 2007Date of Patent: January 24, 2012Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Publication number: 20110201098Abstract: A sensor is disclosed. In one embodiment, the sensor includes an insulating substrate comprising a first zone, a second zone, and an intermediate zone, where the intermediate zone comprises a portion of the second zone that overlaps the first zone. The sensor further comprises a first electrode in the first zone that comprises a first plurality of fingers of a conductive material, a second electrode in the second zone that comprises a second plurality of fingers of the conductive material that are interdigitated with the first plurality of fingers, a plurality of three-dimensional isolation structures, and a plurality of shadow zones, wherein each shadow zone is adjacent to at least one isolation structure and is substantially free of conductive material. The plurality of isolation structures may comprises hills and/or channels.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicants: IMEC, InnogeneticsInventors: Wim Laureyn, Jan Suls, Paul Jacobs
-
Publication number: 20110143443Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.Type: ApplicationFiled: November 10, 2008Publication date: June 16, 2011Applicant: N.V. Innogenetics S. A.Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
-
Patent number: 7955883Abstract: Interdigitated electrode arrays are very promising devices for multi-parameter (bio)sensing, for example the label-free detection of nucleic acid hybridization for diagnostic applications. The current disclosure provides an innovative method for the affordable manufacturing of polymer-based arrays of interdigitated electrodes with ?m-dimensions. The method is based on a combination of an appropriate three-dimensional structure and a single and directional deposition of conductive material. The three-dimensional structure can be realized in a polymer material using a molding step, for which the molds are manufactured by electroplating as a reverse copy of a silicon master structure. In order to ensure sufficient electrical isolation and individual, but convenient, accessibility of the sensors in the array, the interdigitated electrode regions need to be complemented with specific features on the three-dimensional structure. Combined with the use of e.g.Type: GrantFiled: September 6, 2006Date of Patent: June 7, 2011Assignees: IMEC, InnogeneticsInventors: Wim Laureyn, Jan Suls, Paul Jacobs
-
Patent number: 7935490Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.Type: GrantFiled: August 2, 2006Date of Patent: May 3, 2011Assignee: N.V. InnogeneticsInventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein
-
Publication number: 20110059092Abstract: The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being comprised from 11 to 42, and recognises neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.Type: ApplicationFiled: October 24, 2008Publication date: March 10, 2011Applicants: INNOGENETICS NV, SANOFI-AVENTISInventors: Eugeen Vanmechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-bregeon
-
Patent number: 7855052Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.Type: GrantFiled: November 30, 2006Date of Patent: December 21, 2010Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7741461Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularly, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cryptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.Type: GrantFiled: October 19, 2004Date of Patent: June 22, 2010Assignees: Innogenetics N.V., Enterprise Ireland, National University of Ireland GalwayInventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van der Weide
-
Publication number: 20100120121Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: ApplicationFiled: July 12, 2007Publication date: May 13, 2010Applicant: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn